Skip to content
All Podcasts – Lifestyle
Author:
FibroBiologics, Inc.
FibroBiologics Appoints Leigh Steinberg to Board of Directors
August 24, 2026
FibroBiologics Announces Australian Patent Accepted for Cannabidiol Adjuvant Therapy for the Treatment of Degenerative Disc Disease
August 20, 2026
FibroBiologics Announces Chondrocyte Spheroids Demonstrate Cartilage Repair in Preclinical Study of Degenerative Joints
August 18, 2026
FibroBiologics Granted U.S. Patent Covering the Use of Fibroblasts to Enhance Survival and Function of Transplanted Insulin-Producing Islets
August 11, 2026
FibroBiologics Granted European Patent Covering Gene Therapy for the Regeneration of Cartilage
August 5, 2026
FibroBiologics Reports Second Quarter 2026 Financial Results; Progresses Clinical Trial Evaluating Lead Wound Care Candidate
July 31, 2026
FibroBiologics Appoints Kathleen “Kate” Rubins, Ph.D. to Board of Directors
July 9, 2026
FibroBiologics Completes Manufacturing of Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial
July 7, 2026
FibroBiologics to Participate in Fireside Chat at H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
June 30, 2026
FibroBiologics Announces Closing of up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
June 29, 2026
1
2
3
Next Page
→